Neuropsychological measures of attention and memory function in schizophrenia: Relationships with symptom dimensions and serum monoamine activity

Behavioral and Brain Functions

Volumn 1, Issue , 2005, Pages

  Oades, Robert D ^a   Röpcke, Bernd ^a   Henning, Uwe ^b   Klimke, Ansgard ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b University Clinic for Psychiatry and Psychotherapy   (Germany)

Author keywords

Cognition; Disorganised; Dopamine; Ideas of reference; Noradrenaline; Paranoid; Schizophrenia; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; BIPERIDEN; BRAIN MONOAMINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; HOMOVANILLIC ACID; NEUROLEPTIC AGENT; NORADRENALIN; OLANZAPINE; RISPERIDONE; SEROTONIN; SERTINDOLE;

ADULT; ARTICLE; ASSOCIATION; ATTENTION DISTURBANCE; CINGULATE GYRUS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINE BLOOD LEVEL; DOPAMINE METABOLISM; FACE PROFILE; FEMALE; FRONTAL LOBE; HEMISPHERIC DOMINANCE; HUMAN; LEFT HEMISPHERE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MONOAMINERGIC SYSTEM; NEUROPSYCHOLOGICAL TEST; NORADRENALIN BLOOD LEVEL; PARANOIA; PARIETAL LOBE; PATIENT CARE PLANNING; PATTERN RECOGNITION; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; RECALL; RIGHT HEMISPHERE; SCHIZOPHRENIA; SEROTONIN BLOOD LEVEL; SEROTONIN METABOLISM; TASK PERFORMANCE; TEMPORAL LOBE; THOUGHT DISORDER; VERBAL COMMUNICATION; VERBAL MEMORY; VISUAL MEMORY;

EID: 33845214840     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-1-14     Document Type: Article

References (84)

1. Bleuler E: Dementia Praecox oder Gruppe der Schizophrenien. Vienna, Deuticke 1911.
2. Carpenter WT, Kirkpatrick B, Buchanan RW: Schizophrenia: syndromes and diseases. J Psychiatr Res 1999, 33:473-475.
3. Bender S, Müller B, Sartory G, Oades RD: Conditioned blocking and schizophrenia: a replication and study of the role of symptoms, age, onset-age of psychosis and illness-duration. Schizophr Res 2001, 49:157-170.
4. Amin F, Davidson M, Kahn RS, Schmeidler J, Stern R, Knott PJ, Apter SH: Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophr Bull 1995, 21:53-66.
5. Amin F, Silverman JM, Siever LJ, Smith CJ, Knott PJ, Davis KL: Genetic antecedents of dopamine dysfunction in schizophrenia. Biol Psychiatry 1999, 45:1143-1150.
6. Andreasen NC, Olsen S: Negative versus positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982, 39:789-794.
7. Galinowski A, Poirier MF, Aymard N, Leyris A, Beauverie P, Bourdel MC, Loo H: Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol. Acta Psychiatr Scand 1998, 97:458-466.
8. Garver DL, Steinberg JL, McDermott BE, Yao JK, Ramberg JE, Lewis S, Kingsbury SJ: Etiologic heterogeneity of the psychoses: is there a dopamine psychosis? Neuropsychopharmacology 1997, 16:191-201.
9. Zhang ZJ, Peet M, Ramchand CN, Shah S, Reynolds GP: Plasma homovanillic acid in untreated schizophrenia - relationship with symptomatology and sex. J Psychiat Res 2001, 35:23-28.
10. Sharma RP, Javaid JI, Davis JM, Janicak PG: Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period. Biol Psychiatry 1998, 44:488-492.
11. Oades RD, Klimke A, Henning U, Rao ML: Relations of clinical features, subgroups and medication to serum monoamines and schizophrenia. Hum Psychopharmacol 2002, 17:15-27.
12. Pliszka SR, Maas JW, Javors MA, Rogeness GA, Baker J: Urinary catecholamines in attention-deficit hyperactivity disorder with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 1994, 33:1165-1173.
13. Bowers MB, Swigar ME, Jatlow PI, Goicoechea N: Plasma catecholamine metabolites and early response to haloperidol. Clin Psychiatry 1984, 45:248-251.
14. Bowers MB, Swigar ME, Jadow PI, Hoffman FJ, Goicoecha N: Early neuroleptic response: clinical profiles and plasma catecholamine metabolites. J Clin Psychopharmacol 1987, 7:83-86.
15. Sharma RP, Javaid JI, Janicak PG, Faull K, Comaty J, Davis JM: Plasma and CSF HVA before and after pharmacological treatment. Psychiat Res 1989, 28:97-104.
16. Siever LJ: The biology of the boundaries of schizophrenia. In Schizophrenia: Advances in Neuropsychiatry and Psychopharmacology Edited by: Tamminga CA, Schulz SC. New York, Raven Press; 1991.
17. Siever LJ: Biologic factors in schizotypal personality disorders. Acta Psychiat Scand 1994, 90(suppl 384):45-50.
18. Scheepers FE, Gispen-De-Wied CC, Westenberg HG, Kahn RS: The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 2001, 25:468-475.
19. Forrest TJ, Allen DN, Weiner C, Yao JK, Gurklis JA, Van Kammen DP: The HIVA/5-HIAA ratio and cognitive function in schizophrenia. Schizophr Res 2001, 49:52-53.
20. Wieselgren I-M, Lindström LH: CSF levels of HIVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiat Res 1998, 81:101-110.
21. Kahn RS, Davidson M, Knott P, Stern RG, Apter SH, Davis KL: Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia: serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry 1993, 50:599-605.
22. Maas JW, Bowden CL, Miller AL, Javors MA, Funderburg LG, Berman N, Weintraub ST: Schizophrenia, psychosis and cerebral spinal fluid homovanillic acid concentrations. Schizophr Bull 1997, 23:147-154.
23. Butler PD, Harkavy-Friedman JM, Amador XF, Gorman JM: Backward masking in schizophrenia: relationship to medication status, neuropsychological functioning, and dopamine metabolism. Biol Psychiatry 1996, 40:295-298.
24. Waldo MC, Adler LE, Leonard S, Olincy A. Ross RG, Harris JG, Freedman R: Familial transmission of risk factors in the first-degree relatives of schizophrenic people. Biol Psychiatry 2000, 47:231-239.
25. Bender S, Schall U, Wolstein J, Grzella I, Zerbin D, Oades RD: A topographic event-related potential follow-up study on 'pre-pulse inhibition' in first and second episode patients with schizophrenia. Psychiat Res Neuroimaging 1999, 90:41-53.
26. Oades RD, Bender S, Schall U, Klimke A, Balcar A, Thienel R: Improved indices of attention in schizophrenia predicted by increased serotonin metabolism: admission/discharge comparisons in first/second episode patients. Psychophysiology 1999, 36:86.
27. Oades RD, Müller B, Schall U, Bender S, Wolstein J: Automatic vs. controlled attention in schizophrenia: conditioned blocking and sensory gating. Behav Pharmacol 2000, 11:346.
28. Waldo MC, Gerhardt G, Baker NJ, Drebing C, Adler LE, Freedman R: Auditory sensory gating and catecholamine metabolism in schizophrenic and normal subjects. Psychiat Res 1992, 44:21-32.
29. Kahn RS, Harvey PD, Davison M, Keefe RSE, Apter SH, Neale JM, Mohs RC, Davis KL: Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophr Res 1994, 11:217-224.
30. Csernansky JG, King RJ, Faustman WO, Moses JA, Poscher ME: 5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics. Br J Psychiatry 1990, 156:501-507.
31. Zakzanis KK, Kaplan E, Leach L: Neuropsychological differential diagnosis. Lisse, The Netherlands, Swets & Zeitlinger 1999.
32. 2-receptor occupancy. Behav Pharmacol 2000, 11:317-330.
33. Oades RD, Müller BW, Bender S, Sartory G: Neuropsychological indicators of heteromodal cortex (dys)function relevant to the expression and impairment of conditioned blocking measures of selective attention in schizophrenia. Cogn Neuropsychiatry 2001, 6:41-61.
34. American Psychiatric Association: Diagnostic and statistical manual of mental disorders: DSM-IV 4th edition. Washington, D.C; 1994.
35. Benkert O, Hippius H: Psychiatrische Pharmakotherapie 4th edition. Heidelberg, Springer-Verlag; 1986.
36. Rey M-J, Schulz P, Costa C, Dick P, Tissot R: Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 1989, 4:95-104.
37. Schulz P, Rey M-J, Dick P, Tissot R: Guidelines for the dosage of neuroleptics. II: Changing from daily oral to long-acting injectable neuroleptics. Int Clin Psychopharmacol 1989, 4:105-114.
38. Kane JM: Drug therapy: Schizophrenia. New England J Med 1996, 334:34-41.
39. Kay SR, Opler LA, Fizbein A: The Positive and Negative Syndrome Scale (PANSS) Toronto, Canada, Manual Multi-Health Systems; 1992.
40. Benton AL, Hamsher K: Multilingual Aphasia Examination Iowa City, IA, AJA Associates; 1989.
41. Reitan RM: The validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958, 8:271-276.
42. Leung H-C, Skudlarski P, Gatenby JC, Peterson BS, Gore JC: An event-related functional MRI study of the Stroop color word interference task. Cereb Cortex 2000, 10:552-560.
43. MacDonald AW, Cohen JD, Stenger VA, Carter CS: Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 2000, 288:1835-1838.
44. Wechsler D: Wechsler Adult Intelligence Scale-revised (WAIS-R) New York, NY, The Psychological Corporation; 1981.
45. Lansdell H: Relation of extent of temporal removals to closure and visuomotor factors. Percept Mot Skills 1970, 31:491-498.
46. Mooney CM, Ferguson GA: A new closure test. Canad J Psychol 1951, 5:129-133.
47. Wechsler D: The Wechsler Memory Scale-Revised. San Antonio, TX The Psychological Corporation, Harcourt Brace Jovanovich; 1987.
48. Raven JC: Raven-Matrizen-Test: Advanced Progressive Matrices. German language manual Edited by: Kratzmeier H, Horn R. Stuttgart, Germany, Beltz-Verlag; 1976.
49. Eriksson B-M, Persson B-A: Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection. J Chromatogr 1982, 228:143-154.
50. Gypta RN, Whelton C: Determination of plasma homovanillic acid by liquid chromatography with electrochemical detection. J Chromatogr 1992, 582:236-241.
51. Minegishi A, Ishizaki T: Determination of free 3-methoxy-4-hydroxy-phenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr 1984, 311:51-57.
52. Croonenberghs J, Delmeire L, Verkerk R, Lin AH, Meskal A, Neels H, Van der Plancken M, Scharpe S, Deboutte D, Pison G, Maes M: Peripheral markers of serotonergic and noradrenergic function in post-pubertal, Caucasian males with autistic disorder. Neuropsychopharmacology 2000, 22:275-283.
53. Jernej B, Banovic M, Cicin-Sain L, Hranilovic D, Balija M, Oreskovic D, Folnegovic-Smalc V: Physiological characteristics of platelet/ circulatory serotonin: study on a large human population. Psychiat Res 2001, 94:153-162.
54. Dursun SM, Whitaker RP, Andrews H, Reveley MA: Effects of natural ageing on plasma 5-HT turnover in humans. Hum Psychopharmacol 1997, 12:365-367.
55. Thibaut F, Ribeyre J-M, Dourmap N, Menard J-F, Dollfus S, Petit M: Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and non-deficit forms of schizophrenia. Biol Psychiatry 1998, 43:24-30.
56. Lambert GW, Kaye DM, Cox HS, Vaz M, Turner AG, Jennings GL, Esler MD: Regional 5-hydroxyindoleacetic acid production in humans. Life Sci 1995, 57:255-267.
57. Oades RD: Stimulus dimension shifts in patients with schizophrenia, with and without paranoid hallucinatory symptoms, or obsessive compulsive disorder: strategies, blocking and monoamine status. Behav Brain Res 1997, 88:115-132.
58. Himmelhoch S, Taylor SF, Goldman RS, Tandon R: Frontal lobe tasks, antipsychotic medication and schizophrenia syndromes. Biol Psychiatry 1996, 39:227-229.
59. Soper HV, Elliott RO, Reizer AA, Marshall BD: Effects of fenfluramine on neuropsychological and communicative functioning in treatment-refractory schizophrenic patients. J Clin Psychopharmacol 1990, 10:168-175.
60. Malhotra AK, Goldman D, Mazzanti C, Clifton A, Breier A, Pickar D: A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Mol Psychiat 1998, 3:328-332.
61. Duval F, Mokrani MC, Monreal J, Bailey P, Valdebenito M, Crocq MA, Macher JP: Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests. Psychoneurcendocrinol 2003, 28:627-642.
62. Frith CD, Blakemore S-J, Wolpert DM: Explaining the symptoms of schizophrenia: abnormalities in the awareness of action. Brain Res Rev 2000, 31:357-363.
63. Kaneko M, Honda K, Kanno T, Horikoshi R, Manome T, Watanabe A, Kumashiro H: Plasma free 3-methoxy-4-hydroxyphenylglycol in acute schizophrenics before and after treatment. Neuropsychobiol 1992, 25:126-129.
64. Yorkston NJ, Zaki SA, Weller MP, Gruzelier JH, Hirsch SR: DL-propranolol and chlorpromazine following admission for schizophrenia: a controlled comparison. Acta Psychiat Scand 1981, 63:13-27.
65. Freedman R, Kirch DG, Bell J, Adler LE, Pecevich M, Pachtman E, Denver P: Clonidine treatment of schizophrenia: double blind comparison to placebo and neuroleptic drugs. Acta Psychiat Scand 1982, 65:35-45.
66. Nieman DH, Bour LJ, Linszen DH, Goede J, Koelman JHTM, Gersons BPR, Ongeboer de Visser BW: Neuropsychological and clinical correlates of antisaccade task performance in schizophrenia. Neurology 2000, 54:866-871.
67. Luciana M, Collins PF, Depue RA: Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex 1998, 8:218-226.
68. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW: Ketamine-induced NMDA receptor hypofunction as a model of a memory impairment and psychosis. Neuropsychopharmacol 1998, 20:106-118.
69. Stirling JD, Hellewell JSE, Qurashi N: Self-monitoring dysfunction and the schizophrenic symptoms of alien control. Psychol Med 1998, 28:675-683.
70. 11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 2000, 34:35-43.
71. Nibuya M, Kanba S, Sekiya U, Suzuki E, Matsuo Y, Kinishita N, Shintani F, Yagi G, Asai M: Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biol Psychiatry 1995, 38:50-56.
72. Suzuki E, Kanba S, Koshikawa H, Nbuya M, Yagi G, Asai M: Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations. J Psychiat Neurosci 1996, 21:167-171.
73. Amin F, Davidson M, Davis KL: Homovanillic acid measurement in clinical research: a review of methodology. Schizophr Bull 1992, 18:123-148.
74. Nyman H, Nybäck H, Wiesel F-A, Oxenstierna G, Schalling D: Neuropsychological test performance, brain morphological measures and CSF monoamine metabolites in schizophrenic patients. Acta Psychiat Scand 1986, 74:292-301.
75. Jacobsen LK, Rapaport JL: Research update: Childhood onset schizophrenia: implications of clinical and neurobiological research. J Child Psychol Psychiat 1998, 39:101-113.
76. Cabeza R, Nyberg L: Imaging cognition II: an empirical review of 275 PET and fMRI studies. J Cogn Neurosci 2000, 12:1-47.
77. Kemali D, Maj M, Galderisi S, Ariano MG, Starace F: Factors associated with increased noradrenaline levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1990, 14:49-59.
78. Van Kammen DP, Kelley ME, Yao JK, Gilbertson MW, Gurklis JA, Inosaka T, Saito H, Peters JL, Sato M: Predicting haloperidol treatment response in chronic schizophrenia. Psychiat Res 1996, 64:47-58.
79. Di Rocco A, Bottiglieri T, Dorfman D, Werner P, Morrison C, Simpson D: Decreased homovanillic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clin Neuropharmacol 2000, 23:190-194.
80. Amin F, Seeman TE, Mohs RC, Davidson M, Knott P, Berkman LF, Albert M, Blazer D: Plasma homovanillic acid and performance on motor and cognitive tasks in community dwelling elderly. Neuropsychopharmacol 1994, 10:29-35.
81. Gilbertson MW, Yao JK, van Kammen DP: Memory and plasma HVA changes in schizophrenia: are they episode markers? Biol Psychiatry 1994, 35:203-206.
82. Medalia A, Gold J, Merriam A: The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 1988, 3:249-271.
83. Oades RD: The role of noradrenaline in tuning and dopamine in switching between signals in the CNS. Neurosci Biobehav Rev 1985, 9:261-283.
84. Brauns H, Haun D, Steinmann S: The construction of an internationally comparable classification by class. In (Erwerbsstatische Besonderheiten am Beispiel von Labour Force Surveys der Bundesrepublik Deutschland, Frankreichs, Großbritanniens und Ungarns.) Arbeitspapiere Arbeitsbereich 1/22 Mannheim Center for European Social Research (MZES), Mannheim; 1997.